| Literature DB >> 22869091 |
Yao-Chung Liu1, Jyh-Pyng Gau, Ying-Chung Hong, Yuan-Bin Yu, Liang-Tsai Hsiao, Jin-Hwang Liu, Tzeon-Jye Chiou, Po-Min Chen, Cheng-Hwai Tzeng.
Abstract
Large pericardial effusion (LPE) with cardiac tamponade is a rare but life-threatening complication in adults undergoing hematopoietic stem cell transplantation (HSCT). The incidence and pathophysiology have not been well defined. We retrospectively reviewed 601 patients (≧18 years of age) receiving HSCT (262 autologous, 189 siblings, and 150 unrelated donors) in our center from January 2001 to September 2011. We described the incidence, clinical characteristics, treatment, and outcome. In total, six patients (0.998 %) developed seven episodes (1.16 %) of LPEs with cardiac tamponade. One patient underwent unrelated allografts and the other five patients received sibling allografts. The median day of detecting LPE were 176 in the six patients and 241 in the four late-onset patients (range, 9-369). All patients had normal cardiac function before HSCT. Two patients developed LPE early after conditioning, considered as cardiac toxicity resulting from high-dose cyclophosphamide. Four patients had chronic graft-versus-host disease (GVHD) involving lung, skin and sicca syndrome concomitant with or preceding the development of LPE. All episodes of cardiac tamponade were effectively managed by pericardiocentesis and enhanced immunosuppression. In conclusion, LPE and cardiac tamponade may develop after allogeneic HSCT, either with sibling or matched unrelated donor. The etiology is probably related to chronic GVHD in cases of late onset. Emergent pericardiocentesis and enhanced immunosuppression can effectively control this life-threatening complication.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22869091 DOI: 10.1007/s00277-012-1541-z
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673